BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

886 related articles for article (PubMed ID: 21941203)

  • 1. Predictive value of fragmented QRS in primary prevention implantable cardioverter defibrillator recipients with left ventricular dysfunction.
    Forleo GB; Della Rocca DG; Papavasileiou LP; Panattoni G; Sergi D; Duro L; Mahfouz K; Magliano G; Santini L; Romeo F
    J Cardiovasc Med (Hagerstown); 2011 Nov; 12(11):779-84. PubMed ID: 21941203
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fragmented QRS and mortality risk in patients with left ventricular dysfunction.
    Cheema A; Khalid A; Wimmer A; Bartone C; Chow T; Spertus JA; Chan PS
    Circ Arrhythm Electrophysiol; 2010 Aug; 3(4):339-44. PubMed ID: 20511537
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Implantable cardioverter-defibrillator in patients with hypertrophic cardiomyopathy: efficacy and complications of the therapy in long-term follow-up.
    Syska P; Przybylski A; Chojnowska L; Lewandowski M; Sterliński M; Maciag A; Gepner K; Pytkowski M; Kowalik I; Maczyńska-Mazuruk R; Ruzyłło W; Szwed H
    J Cardiovasc Electrophysiol; 2010 Aug; 21(8):883-9. PubMed ID: 20132378
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of elapsed time from coronary revascularization to implantation of a cardioverter defibrillator on long-term survival in the MADIT-II trial.
    Barsheshet A; Goldenberg I; Moss AJ; Huang DT; Zareba W; McNitt S; Klein HU; Guetta V
    J Cardiovasc Electrophysiol; 2011 Nov; 22(11):1237-42. PubMed ID: 21615813
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prophylactic catheter ablation for induced monomorphic ventricular tachycardia in patients with implantable cardioverter defibrillators as primary prevention.
    Hayashi T; Fukamizu S; Hojo R; Komiyama K; Tanabe Y; Tejima T; Soejima K; Nishizaki M; Hiraoka M; Ako J; Momomura S; Sakurada H
    Europace; 2013 Oct; 15(10):1507-15. PubMed ID: 23603305
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Use of primary prevention implantable cardioverter-defibrillators in a population-based cohort is associated with a significant survival benefit.
    Parkash R; Sapp JL; Basta M; Doucette S; Thompson K; Gardner M; Gray C; Brownell B; Kidwai H; Cox J
    Circ Arrhythm Electrophysiol; 2012 Aug; 5(4):706-13. PubMed ID: 22685111
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Implantable cardioverter defibrillator for primary prevention in patients with severe ventricular dysfunction awaiting heart transplantation.
    Cantero-Pérez EM; Sobrino-Márquez JM; Grande-Trillo A; Lage-Gallé E; Rangel-Sousa D; Esteve-Ruiz IM; Martínez-Martínez A
    Transplant Proc; 2013; 45(10):3659-61. PubMed ID: 24314988
    [TBL] [Abstract][Full Text] [Related]  

  • 8. QRS Fragmentation and QTc Duration Relate to Malignant Ventricular Tachyarrhythmias and Sudden Cardiac Death in Patients with Hypertrophic Cardiomyopathy.
    Debonnaire P; Katsanos S; Joyce E; VAN DEN Brink OV; Atsma DE; Schalij MJ; Bax JJ; Delgado V; Marsan NA
    J Cardiovasc Electrophysiol; 2015 May; 26(5):547-55. PubMed ID: 25648421
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Outcomes After Implantable Cardioverter-Defibrillator Generator Replacement for Primary Prevention of Sudden Cardiac Death.
    Madhavan M; Waks JW; Friedman PA; Kramer DB; Buxton AE; Noseworthy PA; Mehta RA; Hodge DO; Higgins AY; Webster TL; Witt CM; Cha YM; Gersh BJ
    Circ Arrhythm Electrophysiol; 2016 Mar; 9(3):e003283. PubMed ID: 26921377
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of age and medical comorbidity on the effectiveness of implantable cardioverter-defibrillators for primary prevention.
    Chan PS; Nallamothu BK; Spertus JA; Masoudi FA; Bartone C; Kereiakes DJ; Chow T
    Circ Cardiovasc Qual Outcomes; 2009 Jan; 2(1):16-24. PubMed ID: 20031808
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Implantable cardioverter-defibrillators in patients with CKD: a propensity-matched mortality analysis.
    Nakhoul GN; Schold JD; Arrigain S; Harb SC; Jolly S; Wilkoff BL; Nally JV; Navaneethan SD
    Clin J Am Soc Nephrol; 2015 Jul; 10(7):1119-27. PubMed ID: 26111859
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Can QRS scoring predict left ventricular scar and clinical outcomes?
    Rosengarten JA; Scott PA; Chiu OK; Shambrook JS; Curzen NP; Morgan JM
    Europace; 2013 Jul; 15(7):1034-41. PubMed ID: 23493411
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of left ventricular ejection fraction on occurrence of ventricular events in defibrillator patients with coronary artery disease.
    Schaer B; Sticherling C; Szili-Torok T; Osswald S; Jordaens L; Theuns DA
    Europace; 2011 Nov; 13(11):1562-7. PubMed ID: 21712284
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Factors predisposing to ventricular tachyarrhythmia leading to appropriate ICD intervention in patients with coronary artery disease or non-ischaemic dilated cardiomyopathy.
    Lelakowski J; Piekarz J; Rydlewska A; Majewski J; Senderek T; Ząbek A; Małecka B
    Kardiol Pol; 2012; 70(12):1264-75. PubMed ID: 23264245
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Determinants of patient survival rate after implantation of a cardioverter-defibrillator without resynchronisation capability.
    Lelakowski J; Piekarz J; Rydlewska A; Majewski J; Senderek T; Ząbek A; Małecka B
    Kardiol Pol; 2012; 70(11):1099-110. PubMed ID: 23180517
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Survival and appropriate device interventions in recipients of cardioverter defibrillators implanted for the primary versus secondary prevention of sudden cardiac death.
    Stockburger M; Krebs A; Nitardy A; Habedank D; Celebi O; Knaus T; Dietz R
    Pacing Clin Electrophysiol; 2009 Mar; 32 Suppl 1():S16-20. PubMed ID: 19250084
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prophylactic implantable cardioverter defibrillator treatment in patients with end-stage heart failure awaiting heart transplantation.
    Fröhlich GM; Holzmeister J; Hübler M; Hübler S; Wolfrum M; Enseleit F; Seifert B; Hürlimann D; Lehmkuhl HB; Noll G; Steffel J; Falk V; Lüscher TF; Hetzer R; Ruschitzka F
    Heart; 2013 Aug; 99(16):1158-65. PubMed ID: 23813845
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Predictors of appropriate implantable cardioverter defibrillator (ICD) therapy in primary prevention patients with ischemic and nonischemic cardiomyopathy.
    Verma A; Sarak B; Kaplan AJ; Oosthuizen R; Beardsall M; Wulffhart Z; Higenbottam J; Khaykin Y
    Pacing Clin Electrophysiol; 2010 Mar; 33(3):320-9. PubMed ID: 19796352
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The need to modify patient selection to improve the benefits of implantable cardioverter-defibrillator for primary prevention of sudden death in non-ischaemic dilated cardiomyopathy.
    Disertori M; Quintarelli S; Mazzola S; Favalli V; Narula N; Arbustini E
    Europace; 2013 Dec; 15(12):1693-701. PubMed ID: 23946316
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sex differences in implantable cardioverter-defibrillator implantation indications and outcomes: lessons from the Nationwide Israeli-ICD Registry.
    Amit G; Suleiman M; Konstantino Y; Luria D; Kazatsker M; Chetboun I; Haim M; Gavrielov-Yusim N; Goldenberg I; Glikson M;
    Europace; 2014 Aug; 16(8):1175-80. PubMed ID: 24554524
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 45.